KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Xylem (XYL) Research & Development (2016 - 2026)

Xylem has reported Research & Development over the past 17 years, most recently at $56.0 million for Q1 2026.

  • For Q1 2026, Research & Development changed 0.0% year-over-year to $56.0 million; the TTM value through Mar 2026 reached $226.0 million, changed 0.44%, while the annual FY2025 figure was $226.0 million, 1.74% down from the prior year.
  • Research & Development for Q1 2026 was $56.0 million at Xylem, down from $60.0 million in the prior quarter.
  • Over five years, Research & Development peaked at $61.0 million in Q3 2023 and troughed at $47.0 million in Q3 2022.
  • A 5-year average of $55.9 million and a median of $56.0 million in 2025 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: rose 29.79% in 2023 and later fell 9.84% in 2024.
  • Year by year, Research & Development stood at $54.0 million in 2022, then rose by 11.11% to $60.0 million in 2023, then fell by 3.33% to $58.0 million in 2024, then grew by 3.45% to $60.0 million in 2025, then fell by 6.67% to $56.0 million in 2026.
  • Business Quant data shows Research & Development for XYL at $56.0 million in Q1 2026, $60.0 million in Q4 2025, and $52.0 million in Q3 2025.